Treatment of chronic constipation with cisapride and placebo

Abstract

The effect of cisapride (20 mg bid), a new prokinetic drug, on bowel habits and laxative consumption was studied in patients with idiopathic painless constipation and chronic laxative intake. After a four week base line period, spontaneous defection (frequency without laxative intake) and total defecation (total frequency) were measured. Patients with a spontaneous defecation of less than three stools per week entered the treatment period and were randomly assigned to double blind treatment with either cisapride (n = 64) or placebo (n = 62). After eight weeks of treatment, a four week run out phase on single blind placebo medication was conducted. Cisapride and placebo increased spontaneous stool frequency from 1.1 ± 0.2 SEM to 3.0 ± 0.2 per week (p < 0.001) and from 1.2 ± 0.1 to 1.5 ± 0.2 (p > 0.05), respectively. Laxative consumption was decreased from 3.6 ± 0.3 to 1.8 ± 0.2 doses/week by cisapride (p < 0.001) and from 3.3 ± 0.3 to 2.8 ± 0.3 by placebo (p < 0.05). Both drugs improved constipation as assessed by the patient by means of a visual analogue scale, but cisapride did so to a larger extent than placebo. The effects of cisapride partly outlasted active medication by at least four weeks. It is concluded that cisapride improves bowel habits in patients with idiopathic constipation and reduces laxative consumption.